Chimeric antigen receptor‐modified human regulatory T cells that constitutively express IL‐10 maintain their phenotype and are potently suppressive

Clinical trials of Treg therapy in transplantation are currently entering phases IIa and IIb, with the majority of these employing polyclonal Treg populations that harbor a broad specificity. Enhancing Treg specificity is possible with the use of chimeric antigen receptors (CARs), which can be custo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohseni, Yasmin R., Saleem, Adeel, Tung, Sim L., Dudreuilh, Caroline, Lang, Cameron, Peng, Qi, Volpe, Alessia, Adigbli, George, Cross, Amy, Hester, Joanna, Farzaneh, Farzin, Scotta, Cristiano, Lechler, Robert I., Issa, Fadi, Fruhwirth, Gilbert O., Lombardi, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Immunomodulation and immune therapies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581768/
https://www.ncbi.nlm.nih.gov/pubmed/34320225
http://dx.doi.org/10.1002/eji.202048934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581768/
https://www.ncbi.nlm.nih.gov/pubmed/34320225
http://dx.doi.org/10.1002/eji.202048934

Ejemplares similares